Gelonghui August 9?Some investors asked 300937.SZ, "what are the main factors that benefit from the company's half-year performance growth?" Will the ongoing pharmaceutical rectification have a positive impact on the company? "
Drug Tesco replied that the company's semi-annual performance growth mainly benefited from the company's business development, and the company had disclosed the main reasons for the increase in the current performance in the "2023 semi-Annual results Forecast". The company will disclose the current operating results in detail in the 2023 semi-annual report. At present, the reorganization of the direction of medicine will not have an impact on the company.